Pykus Therapeutics Selected to Present at the Euretina Special Focus Meeting on Ocular Endotamponades in Athens, Greece

-- Pykus to provide an update of its ongoing Clinical Pilot Study evaluating PYK-2101, a First-in-Class Retinal Sealant, for the treatment of retinal detachment --

CAMBRIDGE, Mass., March 13, 2025 /PRNewswire/ -- Pykus Therapeutics, Inc. ("Pykus" or the "Company"), a clinical-stage medical technology company, announced today that it will present an overview of its investigational retinal sealant, PYK-2101, at the Euretina Special Focus Meeting on Ocular Endotamponades on March 15, 2025 in Athens. PYK-2101 aims to provide a transformative experience for patients undergoing retinal surgery, offering rapid visual recovery, enhanced surgical outcomes and a dramatically improved patient recovery experience. Currently, PYK-2101 is being investigated in a prospective, multicenter clinical trial in patients with retinal detachment in Australia.

Presentation Details:

• Title: Alternative investigational biodegradable hydrogel sealant for retinal breaks - principles and clinical pilot data
  
  
• Presenter: Friedrich Asmus, MD, Chief Development Officer, Pykus Therapeutics
  
  
• Time: March 15, 2025, 12:10 pm CET
  
  
• Location: InterContinental Hotel, Athens Greece

About PYK-2101: 
PYK-2101 is a patented, first-in-class biodegradable retinal hydrogel sealant. The Company is pursuing an initial indication for the treatment of retinal detachment. PYK-2101 offers the opportunity to dramatically improve and accelerate visual recovery following retinal detachment surgery by sealing retinal breaks directly without having to obscure vision, while eliminating the need for patients to position "face-down" after surgery. Compared to the current standard-of-care, which involves filling the eye with endotamponade agents such as intraocular gases or silicone oil, PYK-2101 aims to dramatically enhance the patient experience and improve surgical outcomes.

About Retinal Detachment Surgery and Vitrectomy Surgery:
Retinal Detachment is amongst the most common indications for undergoing retinal surgery. Nearly two million retinal surgeries, or vitrectomies, are performed annually worldwide. The current standard-of-care for retinal detachment surgery subjects patients to significant post-operative burdens and prolonged visual recovery. Approximately 20 percent of cases fail requiring repeat surgery, often resulting in permanent vision loss.

About Euretina and the Special Focus Meeting: 
The 2025 Euretina Special Focus Meeting is on the topic of Ocular Endotamponades. The full day program [LINK: https://euretina.org/sfm-2025/about/] will provide a comprehensive overview on the uses of various endotamponade agents, from the fundamentals of agents that have been in use for more than 30 years, to the latest developments and innovations in the field.

About Pykus Therapeutics: 
Pykus Therapeutics, Inc., based in Cambridge, MA, is a clinical-stage, medical technology company dedicated to advancing treatments for retinal and other ophthalmic diseases. Using technology originally developed by and licensed from the Mass. Eye and Ear Infirmary (now part of Mass General Brigham) at Harvard Medical School, Pykus aims to deliver transformative solutions to improve surgical outcomes and enhance patient care. For more information, visit www.pykustherapeutics.com.

Contact:
Kelsey-Ann Leslie
Pykus Therapeutics
[email protected]

SOURCE Pykus Therapeutics